口服普萘洛尔联合外用盐酸倍他洛尔治疗8例眶周高风险婴幼儿血管瘤的疗效和安全性评价

doi:10.19438/j.cjoms.2020.03.015

中国口腔颌面外科杂志 ›› 2020, Vol. 18 ›› Issue (3): 264-268.doi: 10.19438/j.cjoms.2020.03.015

口服普萘洛尔联合外用盐酸倍他洛尔治疗8例眶周高风险婴幼儿血管瘤的疗效和安全性评价

李红, 周昱川, 龚忠诚, 孙杨, 凌彬

新疆医科大学第一附属医院·附属口腔医院颌面肿瘤外科,新疆维吾尔自治区口腔医学研究所,新疆乌鲁木齐 830054

收稿日期:2019-10-31 修回日期:2020-01-14 发布日期:2020-06-18
通讯作者: 凌彬,E-mail:34527623@qq.com
作者简介:李红（1992-）,女,在读硕士研究生,E-mial:404950863@qq.com
基金资助:
中华口腔医学会西部口腔医学临床科研基金(CSA-W2019-01)

Oral propranolol combined with topical betaxolol for 8 children with high-risk infantile hemangiomas involving periocular region

LI Hong, ZHOU Yu-chuan, GONG Zhong-cheng, SUN Yang, LING Bin

Oncological Department of Oral and Maxillofacial Surgery, First Affiliated Hospital of Xinjiang Medical University/Hospital of Stomatology; Institute of Stomatology, Xinjiang Uygur Autonomous Region. Urumuqi 830054, Xinjiang Uygur Autonomous Region, China

Received:2019-10-31 Revised:2020-01-14 Published:2020-06-18

摘要/Abstract

摘要： 目的评价口服普萘洛尔联合外用盐酸倍他洛尔滴眼液治疗眶周婴幼儿血管瘤的临床疗效和安全性。方法对2014年8月—2019年1月就诊于新疆医科大学第一附属医院·附属口腔医院的8例高风险眶周婴幼儿血管瘤,给予口服普萘洛尔,剂量为0.5~2 mg/（kg·d）;结合外敷盐酸倍他洛尔滴眼液,2次/d,10 min/次,联合用药6个月~1年或瘤体完全治愈。比较用药前、后瘤体面积、厚度、颜色、局部血流峰值,结合患儿用药期间的不良反应,评估临床疗效及安全性。采用SPSS 23.0软件包对数据进行统计学分析。结果 8例患儿平均疗程为9.4个月,停药时平均效果评分为77分,疗效评价为4例Ⅳ级,4例Ⅲ级。用药期间无严重不良反应发生。结论口服普萘洛尔联合外用盐酸倍他洛尔滴眼液治疗眶周高风险婴幼儿血管瘤安全有效。

关键词: 婴幼儿血管瘤, 普萘洛尔, 盐酸倍他洛尔, 眶周

Abstract: PURPOSE: To assess the efficacy and safety of oral propranolol combined with betaxolol for high-risk infantile hemangiomas involving periocular region. METHODS: From August 2014 to January 2019 in 8 pediatric patients with high-risk hemangiomas, propranolol was administered orally at a daily dose of 0.5-2 mg/kg, betaxolol was applied to the tumor surface for ten minutes twice a day. The treatment lasted for half to one year or until a full recovery was achieved. The efficiency and safety of this treatment was assessed based on the changes of size, thickness, color, local peak systolic velocity before and after treatment and side effects during the therapy. SPSS 23.0 software package was used for statistical analysis. RESELTS: The mean treatment duration was 9.4 months and the mean score of efficacy was 77 points of 8 patients. The clinical response were evaluated as four patients for grade Ⅳ and another four for grade Ⅲ. No severe complications were observed. CONCLUSIONS: Oral propranolol combined with topical betaxolol is an effective and safe treatment for high-risk infantile hemangiomas involving periocular region.

Key words: Infantile hemangiomas, Propranolol, Betaxolol, Periocular region

中图分类号:

R739.8

李红, 周昱川, 龚忠诚, 孙杨, 凌彬. 口服普萘洛尔联合外用盐酸倍他洛尔治疗8例眶周高风险婴幼儿血管瘤的疗效和安全性评价[J]. 中国口腔颌面外科杂志, 2020, 18(3): 264-268.

LI Hong, ZHOU Yu-chuan, GONG Zhong-cheng, SUN Yang, LING Bin. Oral propranolol combined with topical betaxolol for 8 children with high-risk infantile hemangiomas involving periocular region[J]. China J Oral Maxillofac Surg, 2020, 18(3): 264-268.

参考文献

[1] Léauté-Labrèze C, Harper JI, Hoeger PH.Infantile haemangioma[J]. Lancet, 2017, 390(10089): 85-94.
[2] Adams DM, Ricci KW.Infantile hemangiomas in the head and neck region[J]. Otolaryngol Clin North Am, 2018, 51(1): 77-87.
[3] Hutchinson AK, Kraker RT, Pineles SL, et al.The use of β-blockers for the treatment of periocular hemangiomas in infants[J]. Ophthalmology, 2019, 126(1): 146-155.
[4] 周昱川, 凌彬, 尹小朋, 等. 外涂盐酸倍他洛尔滴眼液治疗7例表浅型婴幼儿血管瘤疗效观察[J]. 中国口腔颌面外科杂志, 2017, 15(5): 438-441.
[5] 中华医学会整形外科分会血管瘤和脉管畸形学组. 血管瘤和脉管畸形的诊断及治疗指南(2019版)[J]. 组织工程与重建外科杂志, 2019, 15(5): 277-317.
[6] 郑家伟, 王绪凯, 秦中平, 等. 口服普萘洛尔治疗婴幼儿血管瘤中国专家共识[J]. 上海口腔医学, 2016, 25(3): 257-260.
[7] 凌彬, 刘洁, 张静, 等. 缺氧诱导因子1α在普萘洛尔治疗婴幼儿血管瘤患者中的表达与意义[J]. 口腔医学研究, 2014, 30(7): 659-662.
[8] Achauer BM, Chang CJ, Vander Cam VM.Management of hemangioma of infancy: review of 245 patients[J]. Plast Reconstr Surg, 1997, 99(5): 1301-1308.
[9] Haggstrom AN, Baselga E, Chamlin SL, et al.Localized infantile hemangiomas of the face and scalp: Predilection for the midline and periorbital and perioral skin[J]. Pediatr Dermatol, 2018, 35(6): 774-779.
[10] Zhao J, Huang AH, Rainer BM, et al.Periocular infantile hemangiomas: Characteristics, ocular sequelae, and outcomes[J]. Pediatr Dermatol, 2019, 36(6): 830-834.
[11] Samuelov L, Kinori M, Rychlik K, et al.Risk factors for ocular complications in periocular infantile hemangiomas[J]. Pediatr Dermatol, 2018, 35(4): 458-462.
[12] 邓佳欣, 陈悦, 陈媛, 等. 口腔颌面部血管瘤治疗的研究进展[J]. 口腔疾病防治, 2019, 27(1): 57-62.
[13] 宫贺, 徐大朋, 李越霄, 等. 0.5%马来酸噻吗洛尔滴眼液联合普萘洛尔治疗婴幼儿血管瘤疗效分析[J]. 中国口腔颌面外科杂志, 2014, 12(5): 441-445.
[14] Solman L, Glover M, Beattie PE, et al.Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology consensus guidelines[J]. Br J Dermatol, 2018, 179(3): 582-589.
[15] Krowchuk DP, Frieden IJ, Mancini AJ, et al.Clinical practice guideline for the management of infantile hemangiomas[J]. Pediatrics, 2019, 143(1): e20183475.
[16] Hagen R, Ghareeb E, Jalali O, et al.Infantile hemangiomas: what have we learned from propranolol?[J]. Curr Opin Pediatr, 2018, 30(4): 499-504.
[17] 诸骏仁, 桑国卫. 中华人民共和国药典临床用药须知: 化学药和生物制品卷(2005年版) [M]. 北京: 人民卫生出版社, 2005: 181-184.
[18] Chantasart D, Hao J, Li SK.Evaluation of skin Permeation of β-blockers for topical drug delivery[J]. Pharm Res, 2013, 30(3): 866-877.
[19] Zhang Q, Chantasart D, Li SK.Evaluation of blocker gel and effect of dosing volume for topical delivery[J]. J Pharm Sci, 2015, 104(5): 1721-1731.
[20] 武会芝, 李勇, 王霞, 等. β受体阻滞药治疗婴幼儿血管瘤作用机制的研究进展[J]. 中国药房, 2016, 27(8): 1143-1146.

口服普萘洛尔联合外用盐酸倍他洛尔治疗8例眶周高风险婴幼儿血管瘤的疗效和安全性评价

Oral propranolol combined with topical betaxolol for 8 children with high-risk infantile hemangiomas involving periocular region

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李晓, 范新东, 郑家伟. 脉管异常的ISSVA分类概要及分子生物学研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(3): 286-290.
[2]	郑家伟, 王绪凯, 秦中平, 范新东, 李凯, 杨耀武, 霍然, 刘少华, 赵吉宏, 汪小勇, 周德凯, 刘学键. 口服普萘洛尔治疗婴幼儿血管瘤中国专家共识（2022版）[J]. 中国口腔颌面外科杂志, 2022, 20(4): 313-319.
[3]	郑家伟, 赵泽亮, 陈启铭. 婴幼儿血管瘤循证治疗现状[J]. 中国口腔颌面外科杂志, 2022, 20(1): 7-14.
[4]	王杞章, 郑家伟. 口服普萘洛尔治疗婴幼儿增殖期血管瘤:英国儿科皮肤病学会共识及临床指南[J]. 中国口腔颌面外科杂志, 2020, 18(6): 548-552.
[5]	顾达, 霍然, 徐广琪, 毕见海, 李尚滨. 局部外用β受体阻滞剂治疗婴幼儿血管瘤的临床应用研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(4): 375-380.
[6]	宋会新, 林春男, 王田友, 付兆臣. 普萘洛尔治疗婴幼儿血管瘤的作用机制研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(2): 182-185.
[7]	刘学键, 刘志鹏, 武宜雷, 邰茂众. 平阳霉素新剂型瘤体内注射治疗婴幼儿血管瘤203例临床分析[J]. 中国口腔颌面外科杂志, 2019, 17(3): 247-250.
[8]	刘诗奇, 羊良慧, 陈国生, 王辉, 房芳, 廖显翔, 麦华明. β肾上腺素受体在舌癌CAL-27细胞系的表达及β受体阻滞剂对其增殖、迁移、侵袭的影响[J]. 中国口腔颌面外科杂志, 2018, 16(5): 391-396.
[9]	张凯驰, 徐大朋, 程沫沙, 王绪凯. 马来酸噻吗洛尔和普萘洛尔治疗婴幼儿表浅型血管瘤的疗效分析[J]. 中国口腔颌面外科杂志, 2017, 15(6): 529-533.
[10]	周昱川，凌彬，龚忠诚，许颖捷，陈青立. 外涂盐酸倍他洛尔滴眼液治疗7例表浅型婴幼儿血管瘤疗效观察[J]. 中国口腔颌面外科杂志, 2017, 15(5): 438-441.
[11]	程沫沙，张凯驰，王绪凯. 普萘洛尔治疗溃疡性婴幼儿血管瘤18例临床分析[J]. 中国口腔颌面外科杂志, 2017, 15(3): 264-267.
[12]	赵志国, 潘遥, 杨东升, 张力平. 口服普萘洛尔治疗婴幼儿鼻部血管瘤临床疗效评价[J]. 中国口腔颌面外科杂志, 2017, 15(2): 147-152.
[13]	赵志国, 潘遥, 杨东升, 张力平. 口服普萘洛尔治疗婴幼儿鼻部血管瘤临床疗效评价[J]. 中国口腔颌面外科杂志, 2017, 15(2): 161-164.
[14]	董建勇, 李凯, 岳琳琳, 李荣慧, 黄莹莹, 刘少华. 口服普萘洛尔对血管瘤患儿体格发育的近期影响[J]. 中国口腔颌面外科杂志, 2016, 14(6): 510-513.
[15]	王菲楠, 范新东. 放射性核素治疗婴幼儿血管瘤的现状[J]. 中国口腔颌面外科杂志, 2016, 14(5): 471-474.